Compass Therapeutics, Inc. Quarterly Depreciation in USD from Q2 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Compass Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q2 2020 to Q1 2024.
  • Compass Therapeutics, Inc. Depreciation for the quarter ending March 31, 2024 was $200K, unchanged year-over-year.
  • Compass Therapeutics, Inc. annual Depreciation for 2023 was $700K, a 12.5% decline from 2022.
  • Compass Therapeutics, Inc. annual Depreciation for 2022 was $800K, a 33.3% increase from 2021.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $200K $0 0% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q1 2023 $200K $0 0% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q3 2022 $200K +$100K +100% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q1 2022 $600K $200K $0 0% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $600K $200K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $100K -$300K -75% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $100K -$300K -75% Apr 1, 2021 Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $200K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q3 2020 $400K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $400K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.